Isomorphic Labs, a Google DeepMind spinoff, will soon start human trials of drugs designed using its Nobel Prize–winning AI protein-folding technology.

Isomorphic Labs, the DeepMind spin-off focused on AI-driven drug discovery, has revealed an exclusive new AI model that scientists say surpasses current benchmarks, offering a glimpse of what AlphaFold 4 may bring to pharmaceutical research and molecular biology.

Isomorphic Labs launches IsoDDE, an AI drug design engine that more than doubles AlphaFold 3's accuracy in predicting protein-ligand structures and binding affinities.